Topline results were announced from a phase 3 trial evaluating Cylembio (imsapepimut and etimupepimut, adjuvanted) in combination with pembrolizumab as a first-line treatment for advanced melanoma.

Roche has found redemption in a precision medicine approach following an earlier Tecentriq trial flop in a broader bladder ...